Mestastop® Solutions logo — Stopping Metastasis, giving life a second chance

Mestastop® Solutions

Stopping Metastasis, giving life a second chance

Founded 2018 United States United States 18 employees Seed Total: $58.00M Biotechnology, Life Sciences

General Information

Company Name Mestastop® Solutions
Founded Year 2018
Location United States United States +2
Founders / Decision Makers
Team member Team member
Employees 18
Industries Biotechnology, Life Sciences
Funding Stage Seed
Social

Get notified when Mestastop® Solutions moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Mestastop® Solutions

Mestastop® Solutions is a biotechnology startup founded in 2018, with its headquarters in the United States. The company's slogan, "Stopping Metastasis, giving life a second chance," highlights its dedication to addressing one of the most critical aspects of cancer. Mestastop focuses on combating metastasis, which is responsible for almost 90% of cancer deaths. Despite advancements in cancer treatment such as targeted therapy and immunotherapy, addressing metastasis remains a significant challenge in the field. Mestastop aims to fill this gap with its unique proprietary platforms, including METAssay, METSCAN, and METVivo. These platforms target the challenges faced in advancing a molecule targeting metastasis, from suitable in vitro models to animal models that closely resemble the biology without alleviating cost and timelines. In line with its mission, Mestastop recently secured a Seed Round investment of INR45.00M on 19 October 2023, with 92 Angels and Malpani Ventures as the participating investors. This funding is a testament to the potential of Mestastop's innovative approach to combating metastasis and reflects investor confidence in the company's ability to make a significant impact in the biotechnology sector.

Taxonomy: cancer treatment, metastasis, drug discovery, anti-metastasis, tumor microenvironment, immunosuppression, genetic engineering, cell biology, clinical sampling, targeted therapy, immunotherapy, pharmacology, molecular biology, oncology

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 2
Investor Investor
19 Oct 2023
Seed Round •••••• 2 •••• •••• 19 Oct 2021
Seed Round •••••• 1
Investor
22 Sep 2020

Mestastop® Solutions Alternatives & Competitors

Mestastop® Solutions vs
Teclison
Teclison United States

Biotechnology company that specializes in the development of innovative cancer medicines

Series Unknown
9 employees
Biotechnology
Mestastop® Solutions vs

Advancing Early Cancer Detection with Circulating Tumor Cells for Improved Prognosis and Disease Man...

Private Equity
Biotechnology, Health Care
Mestastop® Solutions vs

Epigenetic silencing platform for tumor recurrence repression

Seed
1 employees

FAQ About Mestastop® Solutions

Stopping Metastasis, giving life a second chance
Mestastop® Solutions was founded in 2018.
Mestastop® Solutions is headquartered in United States.
Mestastop® Solutions operates in the following industries: Biotechnology, Life Sciences.
Mestastop® Solutions has approximately 18 employees.
Mestastop® Solutions has completed 3 funding rounds, raising a total of $58.00M. The latest funding stage is Seed.
Top alternatives and competitors to Mestastop® Solutions include Teclison, IV Diagnostics, Repron Therapeutics, The Center for Cancer and Metabolism, MetasTx LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Mestastop® Solutions and Teclison are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Mestastop® Solutions and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy